Research Papers

25 of 222 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Exploring Covalent Bond Formation at Tyr-82 for Inhibition of Ral GTPase Activation.
Landgraf AD; Yeh IJ; Ghozayel MK; Bum-Erdene K; Gonzalez-Gutierrez G; Meroueh SO.
ChemMedChem (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Boroleucine-Derived Covalent Inhibitors of the ZIKV Protease.
Braun NJ; Huber S; Schmacke LC; Heine A; Steinmetzer T.
ChemMedChem (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Imaging of K<sub>Ca</sub> 3.1 Channels in Tumor Cells with PET and Small-Molecule Fluorescent Probes.
Thale I; Maskri S; Grey L; Todesca LM; Budde T; Maisuls I; Strassert CA; Koch O; Schwab A; Wünsch B.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Imidazolylpyrrolone-Based Small Molecules as Anticancer Agents for Renal Cell Carcinoma.
Sousa A; Pontes O; Andrade J; Baltazar F; Costa M; Proença F.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI-001 in in vitro Models of Prostate Cancer Drug Resi…
Nicolescu RCB; Maylin ZR; Pérez-Areales FJ; Iegre J; Pandha HS; Asim M; Spring DR.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Synthesis of a Bifunctional Cross-Bridged Chelating Agent, Peptide Conjugation, and Comparison of <sup>68</sup> Ga Labe…
Damerow H; Wängler B; Schirrmacher R; Fricker G; Wängler C.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Prioritizing Small Sets of Molecules for Synthesis through in-silico Tools: A Comparison of Common Ranking Methods.
Breznik M; Ge Y; Bluck JP; Briem H; Hahn DF; Christ CD; Mortier J; Mobley DL; Meier K.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Importance of Co-operative Hydrogen Bonding in the Apramycin-Ribosomal Decoding A-Site Interaction.
Pirrone MG; Ande C; Haldimann K; Hobbie SN; Vasella A; Böttger EC; Crich D.
ChemMedChem (Unknown)
Published: 2022
2/6 Transparent
Effects of Structural Variations on Antibacterial Properties for Conjugated Diynes Generated through Glaser Hay Couplin…
Hale EA; Ryan HM; McOsker AM; Funk CM; Green LC; Mazur LE; Uthappa DM; Flood BM; Young DD; Hinkle RJ.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
GluN2A-Selective NMDA Receptor Antagonists: Mimicking the U-Shaped Bioactive Conformation of TCN-201 by a [2.2]Paracycl…
Steigerwald R; Chou TH; Furukawa H; Wünsch B.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Sialic Acid 4-N-Piperazine and Piperidine Derivatives Bind with High Affinity to the P. mirabilis Sialic Acid Sodium So…
Bozzola T; Johnsson RE; Nilsson UJ; Ellervik U.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Identification of 2,4-Dinitro-Biphenyl-Based Compounds as MAPEG Inhibitors.
Di Micco S; Terracciano S; Pierri M; Cantone V; Liening S; König S; Garscha U; Hofstetter RK; Koeberle A; Werz O; Bruno I; Bifulco G.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Synthesis and Vasorelaxant Activity of Nitrate-Coumarin Derivatives.
Matos MJ; Uriarte E; Seoane N; Picos A; Gil-Longo J; Campos-Toimil M.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
7H-Pyrrolo[2,3-d]pyrimidine-4-amines as Potential Inhibitors of Plasmodium falciparum Calcium-Dependent Protein Kinases.
Seanego TD; Chavalala HE; Henning HH; de Koning CB; Hoppe HC; Ojo KK; Rousseau AL.
ChemMedChem (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
From DC18 to MR07: A Metabolically Stable 4,4'-Oxybisbenzoyl Amide as a Low-Nanomolar Growth Inhibitor of P. falciparum.
Bassanini I; Parapini S; Basilico N; Taramelli D; Romeo S.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Antigiardial Activity of Novel Guanidine Compounds.
Stevens AJ; Abraham R; Young KA; Russell CC; McCluskey SN; Baker JR; Rusdi B; Page SW; O'Handley R; O'Dea M; Abraham S; McCluskey A.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Synthesis and Biological Evaluation of Cardiac Glycosides for Cancer Therapy by Targeting the DNA Damage Response.
Ainembabazi D; Geng X; Gavande NS; Turchi JJ; Zhang Y.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Evaluation of Anticancer Activity of 1,3-Oxazol-4-ylphosphonium Salts in Vitro.
Brusnakov M; Golovchenko O; Velihina Y; Liavynets O; Zhirnov V; Brovarets V.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Synthesis, Biological Evaluation, and Binding Mode of a New Class of Oncogenic K-Ras4b Inhibitors.
Jeuken S; Shkura O; Röger M; Brickau V; Choidas A; Degenhart C; Gülden D; Klebl B; Koch U; Stoll R; Scherkenbeck J.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Targeted Enzymatic VLP-Nanoreactors with β-Glucocerebrosidase Activity as Potential Enzyme Replacement Therapy for Gauc…
Chauhan K; Olivares-Medina CN; Villagrana-Escareño MV; Juárez-Moreno K; Cadena-Nava RD; Rodríguez-Hernández AG; Vazquez-Duhalt R.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Machine Learning Guided Discovery of Non-Hemolytic Membrane Disruptive Anticancer Peptides.
Zakharova E; Orsi M; Capecchi A; Reymond JL.
ChemMedChem (Unknown)
Published: 2022
5/6 Transparent
Data Code Funding Declared
8-Hydroxy-1,6-naphthyridine-7-carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.
Jung E; Majima R; Edwards TC; Soto-Acosta R; Geraghty RJ; Wang Z.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Compound Interaction Screen on a Photoactivatable Cellulose Membrane (CISCM) Identifies Drug Targets.
Melder FTI; Lindemann P; Welle A; Trouillet V; Heißler S; Nazaré M; Selbach M.
ChemMedChem (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Tunable Emissive Ir(III) Benzimidazole-quinoline Hybrids as Promising Theranostic Lead Compounds.
Redrado M; Miñana M; Coogan MP; Concepción Gimeno M; Fernández-Moreira V.
ChemMedChem (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
The First Structure of Human MTHFD2L and Its Implications for the Development of Isoform-Selective Inhibitors.
Scaletti ER; Gustafsson Westergren R; Andersson Y; Wiita E; Henriksson M; Homan EJ; Jemth AS; Helleday T; Stenmark P.
ChemMedChem (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared